200 related articles for article (PubMed ID: 38863829)
21. SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link?
Balmant BD; Torrinhas RS; Rocha IM; Fonseca DC; Formiga FFC; Bonfá ESDO; Borba EF; Waitzberg DL
Nutrition; 2021 May; 85():111115. PubMed ID: 33545540
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory effect on the gastrointestinal system associated with COVID-19.
Delgado-Gonzalez P; Gonzalez-Villarreal CA; Roacho-Perez JA; Quiroz-Reyes AG; Islas JF; Delgado-Gallegos JL; Arellanos-Soto D; Galan-Huerta KA; Garza-Treviño EN
World J Gastroenterol; 2021 Jul; 27(26):4160-4171. PubMed ID: 34326616
[TBL] [Abstract][Full Text] [Related]
23. Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?
Brahma S; Naik A; Lordan R
Clin Nutr ESPEN; 2022 Oct; 51():17-27. PubMed ID: 36184201
[TBL] [Abstract][Full Text] [Related]
24. Gut Microbiota Status in COVID-19: An Unrecognized Player?
Donati Zeppa S; Agostini D; Piccoli G; Stocchi V; Sestili P
Front Cell Infect Microbiol; 2020; 10():576551. PubMed ID: 33324572
[TBL] [Abstract][Full Text] [Related]
25. Roles of the gut microbiota in severe SARS-CoV-2 infection.
Liu Y; Kuang D; Li D; Yang J; Yan J; Xia Y; Zhang F; Cao H
Cytokine Growth Factor Rev; 2022 Feb; 63():98-107. PubMed ID: 35131164
[TBL] [Abstract][Full Text] [Related]
26. Role of Probiotics in the Management of COVID-19: A Computational Perspective.
Nguyen QV; Chong LC; Hor YY; Lew LC; Rather IA; Choi SB
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057455
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
Mirzaei R; Attar A; Papizadeh S; Jeda AS; Hosseini-Fard SR; Jamasbi E; Kazemi S; Amerkani S; Talei GR; Moradi P; Jalalifar S; Yousefimashouf R; Hossain MA; Keyvani H; Karampoor S
Arch Virol; 2021 Jul; 166(7):1819-1840. PubMed ID: 33745067
[TBL] [Abstract][Full Text] [Related]
28. Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.
Hussain I; Cher GLY; Abid MA; Abid MB
Front Immunol; 2021; 12():765965. PubMed ID: 34721437
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome.
Moreno-Corona NC; López-Ortega O; Pérez-Martínez CA; Martínez-Castillo M; De Jesús-González LA; León-Reyes G; León-Juárez M
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834270
[TBL] [Abstract][Full Text] [Related]
30. Gut microbiome and anti-viral immunity in COVID-19.
Rossini V; Tolosa-Enguis V; Frances-Cuesta C; Sanz Y
Crit Rev Food Sci Nutr; 2024; 64(14):4587-4602. PubMed ID: 36382631
[TBL] [Abstract][Full Text] [Related]
31. Impact of COVID-19 on the Intestinal Microbiome.
Venegas-Borsellino C; Sankararaman S; Roche K; Burns J; Landis RM
Curr Nutr Rep; 2021 Dec; 10(4):300-306. PubMed ID: 34813042
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications.
Zhang F; Lau RI; Liu Q; Su Q; Chan FKL; Ng SC
Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):323-337. PubMed ID: 36271144
[TBL] [Abstract][Full Text] [Related]
33. Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route.
de Oliveira AP; Lopes ALF; Pacheco G; de Sá Guimarães Nolêto IR; Nicolau LAD; Medeiros JVR
Med Hypotheses; 2020 Nov; 144():110243. PubMed ID: 33254549
[TBL] [Abstract][Full Text] [Related]
34. Infection, Dysbiosis and Inflammation Interplay in the COVID Era in Children.
Ailioaie LM; Ailioaie C; Litscher G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446047
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 and gut immunomodulation.
Roy K; Agarwal S; Banerjee R; Paul MK; Purbey PK
World J Gastroenterol; 2021 Dec; 27(46):7925-7942. PubMed ID: 35046621
[TBL] [Abstract][Full Text] [Related]
36. Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection.
Krasaewes K; Chaiwarith R; Chattipakorn N; Chattipakorn SC
Life Sci; 2023 Nov; 332():122136. PubMed ID: 37783267
[TBL] [Abstract][Full Text] [Related]
37. Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection.
Trottein F; Sokol H
Cell Rep; 2020 Jul; 32(3):107915. PubMed ID: 32649864
[TBL] [Abstract][Full Text] [Related]
38. A Narrative Review on Gut Microbiome Disturbances and Microbial Preparations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Long COVID.
Jurek JM; Castro-Marrero J
Nutrients; 2024 May; 16(11):. PubMed ID: 38892479
[TBL] [Abstract][Full Text] [Related]
39. Current Drug Targets for Gut Microbiota Biocorrection during the SARS-CoV-2 Pandemic: A Systematic Review.
Sankova MV; Nikolenko VN; Oganesyan MV; Bakhmet AA; Gavryushova LV; Sankov SV; Sinelnikov MY
Curr Drug Targets; 2022; 23(11):1099-1125. PubMed ID: 35440305
[TBL] [Abstract][Full Text] [Related]
40. Regulation of SARS-CoV-2 infection by diet-modulated gut microbiota.
Tieu V; Tibi S; Ling J
Front Cell Infect Microbiol; 2023; 13():1167827. PubMed ID: 37457959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
